Johns Hopkins HIV Guide
Nevirapine
INDICATIONS
FDA
FDA
- Treatment of HIV infection in combination with other antiretroviral agents.
- Due to increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Single dose at time of delivery to prevent perinatal transmission (widely used in developing countries, but risk of NNRTI resistance; combination therapy preferred when available). Risk of hepatitis for women with CD4 >250 does not apply to single dose NVP.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 27, 2014
Citation
Pham, Paul A, et al. "Nevirapine." Johns Hopkins HIV Guide, 2014. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545148/5.2/Nevirapine.
Pham PA, Bartlett JG, Hsu A . Nevirapine. Johns Hopkins HIV Guide. 2014. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545148/5.2/Nevirapine. Accessed June 3, 2023.
Pham, P. A., Bartlett, J. G., & Hsu, A. . (2014). Nevirapine. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545148/5.2/Nevirapine
Pham PA, Bartlett JG, Hsu A . Nevirapine [Internet]. In: Johns Hopkins HIV Guide. ; 2014. [cited 2023 June 03]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545148/5.2/Nevirapine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nevirapine
ID - 545148
A1 - Pham,Paul,Pharm.D.
AU - Bartlett,John,M.D.
AU - Hsu,Alice,Pharm.D.
Y1 - 2014/06/27/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545148/5.2/Nevirapine
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
